Dr. Thomas Karasic, MD
Claim this profileUniversity of Pennsylvania
Studies Cancer
Studies Colorectal Cancer
9 reported clinical trials
17 drugs studied
Area of expertise
1Cancer
Stage IV
PIK3CA positive
Stage III
2Colorectal Cancer
Stage IV
PIK3CA positive
Stage III
Affiliated Hospitals
Clinical Trials Thomas Karasic, MD is currently running
PC14586
for Solid Tumors
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
Recruiting1 award Phase 1 & 25 criteria
Nivolumab + Standard Treatment
for Colorectal Cancer
This phase II trial tests whether adding nivolumab to the usual treatment (encorafenib and cetuximab) works better than the usual treatment alone to shrink tumors in patients with colorectal cancer that has spread to other places in the body (metastatic) or that cannot be removed by surgery (unresectable) and whose tumor has a mutation in a gene called BRAF. Encorafenib is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in the BRAF gene. It works by blocking the action of mutated BRAF that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with encorafenib and cetuximab may be more effective than encorafenib and cetuximab alone at stopping tumor growth and spreading in patients with metastatic or unresectable BRAF-mutant colorectal cancer.
Recruiting1 award Phase 2
More about Thomas Karasic, MD
Clinical Trial Related3 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Thomas Karasic, MD has experience with
- Nivolumab
- Pembrolizumab
- Cabiralizumab
- BMS-986253
- Paricalcitol
- Gemcitabine
Breakdown of trials Thomas Karasic, MD has run
Cancer
Colorectal Cancer
Liver Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Thomas Karasic, MD specialize in?
Thomas Karasic, MD focuses on Cancer and Colorectal Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are PIK3CA positive.
Is Thomas Karasic, MD currently recruiting for clinical trials?
Yes, Thomas Karasic, MD is currently recruiting for 3 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Thomas Karasic, MD has studied deeply?
Yes, Thomas Karasic, MD has studied treatments such as Nivolumab, Pembrolizumab, Cabiralizumab.
What is the best way to schedule an appointment with Thomas Karasic, MD?
Apply for one of the trials that Thomas Karasic, MD is conducting.
What is the office address of Thomas Karasic, MD?
The office of Thomas Karasic, MD is located at: University of Pennsylvania, Philadelphia, Pennsylvania 19104 United States. This is the address for their practice at the University of Pennsylvania.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.